Šuran David, Završnik Tadej, Kokol Peter, Kokol Marko, Sinkovič Andreja, Naji Franjo, Završnik Jernej, Blažun Vošner Helena, Kanič Vojko
Department of Cardiology and Angiology, University Medical Centre Maribor, Ljubljanska ulica 5, 2000 Maribor, Slovenia.
Faculty of Medicine, University of Maribor, Taborska ulica 8, 2000 Maribor, Slovenia.
J Clin Med. 2023 Apr 29;12(9):3220. doi: 10.3390/jcm12093220.
INTRODUCTION: Lipoprotein(a) (Lp(a)) is a well-recognised risk factor for ischemic heart disease (IHD) and calcific aortic valve stenosis (AVS). METHODS: A retrospective observational study of Lp(a) levels (mg/dL) in patients hospitalised for cardiovascular diseases (CVD) in our clinical routine was performed. The Lp(a)-associated risk of hospitalisation for IHD, AVS, and concomitant IHD/AVS versus other non-ischemic CVDs (oCVD group) was assessed by means of logistic regression. RESULTS: In total of 11,767 adult patients, the association with Lp(a) was strongest in the IHD/AVS group (e = 1.010, < 0.001), followed by the IHD (e = 1.008, < 0.001) and AVS group (e = 1.004, < 0.001). With increasing Lp(a) levels, the risk of IHD hospitalisation was higher compared with oCVD in women across all ages and in men aged ≤75 years. The risk of AVS hospitalisation was higher only in women aged ≤75 years (e = 1.010 in age < 60 years, e = 1.005 in age 60-75 years, < 0.05). CONCLUSIONS: The Lp(a)-associated risk was highest for concomitant IHD/AVS hospitalisations. The differential impact of sex and age was most pronounced in the AVS group with an increased risk only in women aged ≤75 years.
引言:脂蛋白(a)(Lp(a))是缺血性心脏病(IHD)和钙化性主动脉瓣狭窄(AVS)公认的危险因素。 方法:对我们临床常规中因心血管疾病(CVD)住院患者的Lp(a)水平(mg/dL)进行回顾性观察研究。通过逻辑回归评估Lp(a)与IHD、AVS以及合并IHD/AVS住院风险与其他非缺血性CVD(oCVD组)的关系。 结果:在总共11767例成年患者中,Lp(a)与IHD/AVS组的关联最强(e = 1.010,<0.001),其次是IHD(e = 1.008,<0.001)和AVS组(e = 1.004,<0.001)。随着Lp(a)水平升高,各年龄段女性以及75岁及以下男性因IHD住院的风险高于oCVD。仅75岁及以下女性因AVS住院的风险更高(年龄<60岁时e = 1.010,年龄60 - 75岁时e = 1.005,<0.05)。 结论:Lp(a)相关风险在合并IHD/AVS住院患者中最高。性别和年龄的差异影响在AVS组最为明显,仅75岁及以下女性风险增加。
J Am Coll Cardiol. 2013-10-23
Biomolecules. 2019-11-21
Front Public Health. 2022
Am J Cardiovasc Drugs. 2022-1